Cyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals)

N/A

Report date: 2026/03/12 20:00:16

Base Information

Drug NameCyclobenzaprine HCl sublingual tablets (Tonix Pharmaceuticals)
Drug Alias NameCyclobenzaprine hydrochloride very low doseVLD-cyclobenzaprineTonmyaKRL-102TNX-102 +[6] 
ClassificationSmall molecules
Mechanisms of ActionHistamine H1 receptor antagonistsSerotonin 2a (5-HT2a) receptor antagonistsAdrenergic receptors alpha-2 antagonists
TargetsHistamine H1 receptorSerotonin 2a (5-HT2a) receptorAdrenergic receptors alpha-2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeStress Disorders, Traumatic, Acute +[12] 
Global Approved IndicationsFibromyalgia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/08/15
Country/TerritoryCanadaUnited StatesKenya
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVela Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesTonix Pharmaceuticals Holding CorpTonix Pharmaceuticals IncUniversity Of North Carolina At Chapel Hill
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Post-Acute COVID-19 SyndromeStress Disorders, Traumatic, Acute +[6] 
Inactive IndicationsNeuromuscular DiseasesNervous System DiseasesRheumatic Diseases +[6] 

Other Information

ATC CodeN/A
Related LinksN/A